This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (23)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: An early increase in coronary death and nonfatal myocardial infarction (MI) in postmenopausal women with coronary heart disease (CHD) taking hormone therapy compared with placebo was an unanticipated adverse outcome in the Heart and Estrogen/progestin Replacement Study (HERS).¹ The time trend for initial risk and later benefit was statistically significant. Two of us (N.K.W. and G.L.K.) involved in the HERS study recognized some striking similarities between the results of this clinical trial in postmenopausal women with those of the Coronary Drug Project (CDP)² (with which all 3 of us were involved), conducted almost 3 decades earlier in men. HERS and CDP are the only large trials of hormone therapy in populations with CHD, and both data sets could be analyzed further owing to our personal involvement. This report compares the primary outcomes of these trials with particular focus on early excess events following initiation of hormone therapy.

Methods

. . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
Stephen Hulley, Deborah Grady, Trudy Bush, Curt Furberg, David Herrington, Betty Riggs, Eric Vittinghoff, and for the Heart and Estrogen/progestin Replacement Study Research Group
JAMA. 1998;280(7):605-613.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen
Dubey et al.
Cardiovasc Res 2005;66:295-306.
ABSTRACT | FULL TEXT  

An Epidemiologist Looks at Hormones and Heart Disease in Women
Barrett-Connor
J. Clin. Endocrinol. Metab. 2003;88:4031-4042.
FULL TEXT  

Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction
Reiner et al.
Blood 2003;102:25-30.
ABSTRACT | FULL TEXT  

Postmenopausal Hormone Replacement Therapy and the Primary Prevention of Cardiovascular Disease
Humphrey et al.
ANN INTERN MED 2002;137:273-284.
ABSTRACT | FULL TEXT  

Postmenopausal Estrogen Replacement and Risk for Venous Thromboembolism: A Systematic Review and Meta-Analysis for the U.S. Preventive Services Task Force
Miller et al.
ANN INTERN MED 2002;136:680-690.
ABSTRACT | FULL TEXT  

Hormones, genetic factors, and gender differences in cardiovascular disease
Rossouw
Cardiovasc Res 2002;53:550-557.
FULL TEXT  

Effects of oestrogen on cardiovascular events in postmenopausal women
Herrington
Eur Heart J Suppl 2001;3:M7-M11.
ABSTRACT  

Postmenopausal hormones and heart disease
Grady and Hulley
J Am Coll Cardiol 2001;38:8-10.
FULL TEXT